Neuromonics Tinnitus Treatment: Third Clinical Trial
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In Brief Objectives: The Neuromonics Tinnitus Treatment combines the use of a novel approach to acoustic stimulation with a structured program of counseling and support by a clinician specifically trained in tinnitus rehabilitation. The distinctive acoustic component has been designed to provide stimulation to auditory pathways deprived by hearing loss, engage positively with the limbic system, and allow intermittent, momentary tinnitus perception within a pleasant and relaxing stimulus, thereby facilitating desensitization to the tinnitus signal. The purposes of this study were (1) to demonstrate the efficacy of the treatment, when enhanced with various modifications since previously reported trials and (2) to test the relative clinical effectiveness of two variations of the approach. In the first, intermittent tinnitus perception was facilitated throughout treatment through the use of a stimulus in which intensity peaks allowed the patients' tinnitus perception to be completely covered up, whereas in the intensity troughs their tinnitus was briefly discernible. In the second, subjects experienced little tinnitus perception while listening to the treatment for the first 2 mo, then experienced intermittent perception. Design: Thirty-five subjects with a predominantly moderate to severe level of tinnitus-related distress before treatment were randomly allocated into one of two treatment groups, corresponding to the two stage-based variations of the Neuromonics Tinnitus Treatment. Participants were provided with a high-fidelity personal sound player with earphones and an acoustic stimulus that had been spectrally modified according to their individual audiometric profile. They were instructed to use the acoustic stimulus for at least 2 hr per day, particularly at those times when their tinnitus was usually disturbing. Each group had equal amounts of clinician time for education, monitoring, and support. Results: At 2, 4, 6, and 12 mo after commencing treatment, both groups displayed clinically and statistically significant improvements in tinnitus distress, awareness, and minimum masking levels as well as loudness discomfort levels. Improvements increased with time over the first 6 mo of therapy, at which time 91% of all subjects across the two groups reported an improvement in tinnitus disturbance (as measured by the Tinnitus Reaction Questionnaire) of at least 40%, with a mean improvement of 65%. Also, 80% of subjects at 6 mo reported a level of tinnitus disturbance that was no longer clinically significant. There was some indication of a more consistent benefit over 12 mo for the group that was provided initially with a high level of tinnitus interaction; however, inter-group differences were not statistically significant. A relation between reported treatment usage (hours per day) and clinical outcomes was observed, suggesting that a “dosage effect” may apply with the stimulus provided. Conclusions: This study found that the Neuromonics Tinnitus Treatment provides rapid and profound improvements to the severity of tinnitus symptoms and their effect on the subject's quality of life. This was a consistent effect, provided by a treatment that subjects reported as being pleasant to use. Both of the stage-based variations of the treatment that were tested in this study were shown to be successful in achieving these outcomes. Results from a clinical trial using two variations to the Neuromonics Tinnitus Treatment program are reported. In the first variation, intermittent tinnitus perception was facilitated during treatment through the use of a stimulus in which intensity peaks allowed the patients’ tinnitus perception to be completely covered up, while in the intensity troughs tinnitus was briefly discernable. In the second variation, subjects experienced little tinnitus perception while listening to the treatment for the first two months, then experienced intermittent perception. Thirty-five subjects with a predominantly moderate to severe level of tinnitus-related distress prior to treatment were randomly allocated into one of two treatment groups, corresponding to these two stage-based variations of the Neuromonics Tinnitus Treatment. At two, four, six and twelve months after commencing treatment, both groups displayed clinically and statistically significant improvements in tinnitus distress, awareness, and minimum masking levels as well as loudness discomfort levels. Improvements increased with time over the first 6 mo of therapy. A relationship between reported treatment usage (hours per day) and clinical outcomes was observed, suggesting that a 'dosage effect’ may apply with the stimulus provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Does sound stimulation have additive effects on cognitive-behavioral treatment of chronic tinnitus?
Hiller, W., & Haerkötter, C. (2005) · Behaviour Research and Therapy · doi:10.1016/j.brat.2004.03.012 · Cited by 83
Cited by
Tinnitus: causes and clinical management
Langguth, B., Kreuzer, P. M., Kleinjung, T., & De Ridder, D. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70160-1 · Cited by 799
Clinical practice guideline: tinnitus
Tunkel, D. E., Bauer, C. A., Sun, G. H., Rosenfeld, R. M., Chandrasekhar, S. S., Cunningham, E. R., Archer, S. M., Blakley, B. W., Carter, J. M., Granieri, E. C., et al. (2014) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599814545325 · Cited by 769
Maladaptive plasticity in tinnitus — triggers, mechanisms and treatment
Shore, S. E., Roberts, L. E., & Langguth, B. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.12 · Cited by 474
A multidisciplinary European guideline for tinnitus: diagnostics, assessment, and treatment
Cima, R. F. F., Mazurek, B., Haider, H., Kikidis, D., Lapira, A., Noreña, A., & Hoare, D. J. (2019) · HNO · doi:10.1007/s00106-019-0633-7 · Cited by 442
Gu, J. W., Halpin, C. F., Nam, E.-C., Levine, R. A., & Melcher, J. R. (2010) · Journal of Neurophysiology · doi:10.1152/jn.00226.2010 · Cited by 310
Metadata
- Authors
- Davis, P. B., Paki, B., & Hanley, P. J.
- Venue
- Ear & Hearing
- Published
- 2007-04
- Volume
- 28
- Issue
- 2
- Pages
- 242-259
- ISSN
- 0196-0202 (ISSN-L)
- OpenAlex
- W1974508656
- Cited by
- 156
- References
- 2
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.